Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527233 | 0.87 | MGAM (0.58) | MGAMCNR2ALDH1A1PTGESALOX5 | |
| SCHEMBL22777233 | 0.87 | MGAM (0.58) | MGAMCNR2ALDH1A1PTGESALOX5 | |
| SCHEMBL5625543 | 0.84 | GRM2 (0.47) | CNR2KDM4EMAPTLMNAHDAC1 | |
| SCHEMBL12405037 | 0.80 | MGAM (0.63) | MGAMCNR2ALDH1A1HPGDHIF1A | |
| SCHEMBL28071638 | 0.80 | RXFP1 (0.56) | CNR2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL69982 | 0.79 | MGAM (0.58) | MGAMCNR2ALDH1A1HPGDHIF1A | |
| SCHEMBL2715968 | 0.79 | MGAM (0.53) | MGAMALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL2211860 | 0.79 | MGAM (0.58) | MGAMCNR2ALDH1A1CYP2C9HPGD | |
| SCHEMBL28433205 | 0.79 | SMN1; SMN2 (0.70) | CNR2ALDH1A1CYP2C9HPGDTDP1 | |
| SCHEMBL9220609 | 0.78 | MGAM (0.61) | MGAMCNR2ALDH1A1HPGDHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-11-13 | — | — | US | disclosed |
| EP-4617264-A1 | ISOINDOLINONE DERIVATIVE HAVING ARYLCYCLOALKYLAMIDE STRUCTURE, AND USE THEREOF | Oncord Bio Inc (KR) | 2025-09-17 | — | — | EP | disclosed |
| EP-4617270-A1 | ISOINDOLINONE DERIVATIVE HAVING QUINOLINE AMIDE STRUCTURE, AND USE THEREOF | Oncord Bio Inc (KR) | 2025-09-17 | — | — | EP | disclosed |
| CN-120152966-A | Isoindolinone derivative with quinolinamide structure and application thereof | 昂科德生物株式会社 | 2025-06-13 | — | — | CN | disclosed |
| EP-4494698-A2 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| US-12139478-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-3661922-B1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-23 | — | — | EP | disclosed |
| EP-4431505-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-09-18 | — | — | EP | disclosed |
| CN-118234721-A | Isoindolinone derivative with glutarimide mother nucleus and application thereof | 韩国化学研究院 | 2024-06-21 | — | — | CN | disclosed |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-20 | — | — | US | disclosed |
| US-20050154039-A1 | 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine | IPSEN PHARMA S.A.S. (FR) | 2005-07-14 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| CN-1617859-A | 5-sulfanyl-4H-1, 2, 4-triazole derivatives and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2005-05-18 | — | — | CN | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| CN-1438993-A | Ethylenediamine derivatives | DAIICHI SEIYAKU CO (JP) | 2003-08-27 | — | — | CN | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-4461896-A | 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1984-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | MGAM 816/4885CNR2 1642/4885ALDH1A1 3858/4885 |
| US-12139478-B2 | Compounds, compositions and methods | EIF4EBP1, EIF4B, EIF4E | MGAM 4178/4885CNR2 3130/4885ALDH1A1 4529/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | MGAM 4056/4885CNR2 1320/4885ALDH1A1 3319/4885 |
| US-20050154039-A1 | 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine | SSTR3, SSTR1, SSTR5 | MGAM 4453/4885CNR2 123/4885ALDH1A1 2784/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | MGAM 4056/4885CNR2 1320/4885ALDH1A1 3319/4885 |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | CRBN, IDH1, IDH2 | MGAM 2514/4885CNR2 3364/4885ALDH1A1 849/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | MGAM 4829/4885CNR2 505/4885ALDH1A1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.